Reimbursed Care Access in Mauritania

Currently classified as a strictly controlled psychotropic substance under Mauritania’s Loi No. 93‑37 and associated annexes; there is no authorized medical program, reimbursement pathway, or lawful recreational use outside of any narrowly authorized research approved by the national health authorities. #.

Currently classified as a strictly controlled psychotropic substance under Mauritania’s Loi No. 93‑37 and associated annexes; there is no authorized medical program, reimbursement pathway, or lawful recreational use outside of any narrowly authorized research approved by the national health authorities. #.

There is no publicly available evidence of a regulatory approval, national reimbursement program, or a structured medical-access pathway for esketamine (Spravato®) in Mauritania. Mauritania’s narcotics/psychotropics law (Loi No. 93‑37) governs controlled substances and their permitted medical/scientific uses through ministerial lists and does not establish any specialist psychedelic-psychiatric reimbursement program; consequently esketamine would only be present if imported and authorized under an exceptional pharmaceutical import permit, private clinic arrangement or approved clinical trial — none of which appear documented in public regulatory records. For the national legal framework see Loi No. 93‑37. #.

Ketamine is an established injectable anesthetic on the WHO Model List of Essential Medicines and is widely used globally — including in low‑resource and developing-country healthcare systems — as a fundamental anesthetic and analgesic agent. Its WHO listing recognizes ketamine’s role as an essential medicine for anesthesia, which supports lawful medical use in countries’ health systems and supply chains. #.

In Mauritania, the national narcotics statute (Loi No. 93‑37) sets criminal penalties for illicit production, trafficking and non‑medical use of stupéfiants and psychotropes while explicitly applying to substances listed by ministerial decree; medical products and anesthetics are therefore handled through the health‑sector regulatory and pharmaceutical importation/dispensing systems rather than through a permissive recreational regime. In practice this means ketamine may be legally procured and used for legitimate medical purposes (e.g., induction/maintenance of anesthesia, analgesia) subject to normal pharmaceutical regulation, hospital formularies and import/wholesale licensing; the national law framework is the controlling reference for permitted medical use. #.

Reimbursement and access: there is no public documentation of a national, formal reimbursement pathway specifically for ketamine‑based psychiatric indications (e.g., for depression) or for outpatient supervised ketamine clinics reimbursed by a national health insurer. Ketamine’s primary role in Mauritania is expected to remain as an essential anesthetic in public and private hospitals (procured through ministry/hospital procurement or private import), not as an insured, standardized psychedelic psychiatric treatment. # #.

Currently classified as a strictly controlled psychotropic substance under Mauritania’s Loi No. 93‑37 and associated annexes; there is no authorized medical program, reimbursement pathway, or lawful recreational use outside of any narrowly authorized research approved by the national health authorities. Traditional preparations containing DMT (e.g., ayahuasca) are likewise not authorized for medical or ritual exemptions in public law. #.

Currently classified as a strictly controlled psychotropic substance under Mauritania’s Loi No. 93‑37 and associated annexes; there is no authorized medical program, reimbursement pathway, or lawful recreational use outside of any narrowly authorized research approved by the national health authorities. #.

Currently classified as a strictly controlled substance under national drug‑control law with no authorized medical use or reimbursement in the public health system; any clinical use would require an approved research protocol. #.

Preparations containing DMT (ayahuasca) are treated as psychotropic substances under Mauritania’s drug‑control framework and have no authorized medical or religious exemption in national legislation; there is no reimbursement or legally recognized therapeutic access outside approved research. #.

Explicitly listed among controlled hallucinogens in the national control framework; there is no authorized medical program, reimbursement, or legal non‑research access. #.

Members of the 2C phenethylamine family are expressly referenced among hallucinogens subject to control under Mauritania’s drug laws; there is no authorized medical/insured access and possession, sale or trafficking are criminal offenses except where possession/use is lawfully authorized for approved research. #.